Newsroom

Sorted by: Latest

-

Insyde® Software Qualifies Firmware for Arm® AGI CPU Platforms

TAIPEI, Taiwan--(BUSINESS WIRE)--OCP APAC SUMMIT -- Insyde® Software, a worldwide provider of UEFI and OpenBMC firmware for AI Infrastructure, today announced that InsydeH2O® UEFI firmware is qualified on Arm® AGI CPU reference platforms, giving platform developers a proven, production-ready firmware foundation for next-generation agentic AI data center deployments. In addition, Insyde has readied its production verified Supervyse® OPF OpenBMC firmware for Arm AGI CPU-based AI server racks. Thi...
-

Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026, succeeding So...
-

Innate Pharma fait progresser lacutamab vers la phase 3 à la suite de son partenariat avec Sobi et nomme un nouveau directeur médical

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que, sous réserve de la clôture de son partenariat stratégique avec Sobi, elle prévoit d’initier l’étude confirmatoire de Phase 3 TELLOMAK-3 évaluant lacutamab dans le lymphome T cutané (CTCL). Innate annonce également la nomination de Markus Jensen au poste de Directeur médical, membre de l’équipe de direction exécutive, à compter du 1e...
-

Pershing Square Holdings, Ltd. UK Regulatory Announcement: Transaction in Own Shares

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 7 August 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 7 August 2026 Number of Public Shares Purchased: 30,175...
-

OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk

NEW YORK & PARIS--(BUSINESS WIRE)--OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essenti...
-

Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology

BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM), a global biopharmaceutical company dedicated to medical dermatology based in Barcelona, today announced a collaboration and licensing agreement with Shenzhen CrystalO Biopharma Technology Co., Ltd. ("CrystalO") to jointly initiate an R&D collaboration for drug discovery in medical dermatology. The collaboration will combine CrystalO's scientific expertise in ion channels with Almirall's experience in medical dermatology research and c...
-

Innate Pharma conclut un partenariat stratégique avec Sobi pour lacutamab dans les lymphomes T

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») et Swedish Orphan Biovitrum AB (publ) (Sobi®) annoncent aujourd’hui un partenariat stratégique permettant le lancement de l’étude confirmatoire de Phase 3 TELLOMAK-3 dans le lymphome T cutané (CTCL), étape clé vers le dépôt d’une demande d’autorisation accélérée de mise sur le marché de lacutamab dans le syndrome de Sézary, un sous-type de CTCL. Dans le cad...
-

Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLO...
-

Silicon Motion Unveils MonTitan™ SSD Reference Design Kit for AI Infrastructure

TAIPEI, Taiwan & MILPITAS, Calif.--(BUSINESS WIRE)--Silicon Motion Technology Corporation (NasdaqGS: SIMO), a global leader in designing and marketing NAND flash controllers for solid-state storage devices, today unveiled its new MonTitan™ SSD Reference Design Kit (RDK), featuring the company’s next-generation patented PerformaShape™ technology. Designed for Agentic AI infrastructure, the platform enables enterprise SSDs to serve as a persistent memory layer supporting KV cache offload and auto...
-

Best’s Market Segment Report: Strengthened by Hard-Market Years, Global Reinsurance Segment Reaches an Inflection Point

OLDWICK, N.J.--(BUSINESS WIRE)--The global reinsurance segment is at a critical inflection point as reinsurers’ strong earnings since 2023 have driven robust capital generation. With reinsurers’ capital now at record levels, growing competition is increasing pressure on reinsurance pricing, particularly in property lines, and according to a new AM Best report, the key question is whether reinsurers can maintain underwriting discipline or will irrational competition emerge leading to another tra...